Cingulate Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CING Nasdaq 8731 https://www.cingulate.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cingulate Inc

Cingulate begins Phase 3 tests of novel treatment for ADHD - Jan 9th, 2023 1:25 pm
Cingulate Kickstarts First Phase 3 Trial For ADHD Candidate, Data Expected In First Half 2023 - Jan 4th, 2023 11:45 am
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD - Jan 4th, 2023 11:45 am
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16 - Dec 1st, 2022 7:00 pm
Cingulate to Participate in Benzinga All Live Access Event - Nov 30th, 2022 8:00 pm
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update - Nov 14th, 2022 11:45 am
Cingulate Inc. to Present at Investor Summit Group's Q4 Conference - Nov 3rd, 2022 11:00 am
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD - Nov 1st, 2022 1:02 pm
Cingulate Shares Fall After Timeline Update For Its Lead Candidate In ADHD - Oct 25th, 2022 11:55 am
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update - Oct 24th, 2022 8:45 pm
Cingulate to Present at LD Micro Investor Conference - Oct 20th, 2022 6:20 pm
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103 - Sep 19th, 2022 10:45 am
Here's Why Cingulate (NASDAQ:CING) Must Use Its Cash Wisely - Aug 26th, 2022 11:46 am
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update - Aug 11th, 2022 10:45 am
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year - Jul 25th, 2022 5:45 pm
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders - Jun 23rd, 2022 11:00 am
UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022 - Jun 21st, 2022 12:43 pm
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational - Jun 17th, 2022 4:45 pm
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event - Jun 2nd, 2022 6:40 pm
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders - May 24th, 2022 10:45 am